Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Power wheelchair fraud rolled back

This article was originally published in The Gray Sheet

Executive Summary

Unpaid Medicare claim rate is 98.4% for power wheelchairs in Harris County, Texas over the past year, wheelchair distributor The Scooter Store says. CMS' anti-fraud campaign, "Operation Wheeler Dealer," launched in September 2003, singled out Harris County as an area where potential billing fraud appeared "most egregious" and required CMS staff to personally signoff on payments for claims in the region (1"The Gray Sheet" Sept. 15, 2003, p. 4). Medicare paid for more than 31,000 power chairs in 2002 in Harris County, over 10 times the 2001 total of 3,000. TSS charges that the "sharply restrictive" claims review process for Harris represents "geographical discrimination." The firm notes a 95% approval rate for its Medicare power wheelchair claims nationwide...

You may also be interested in...



Power Wheelchairs Targeted For Inherent Reasonableness Price Adjustments

CMS plans to develop inherent reasonableness review guidelines to ensure appropriate Medicare payments for motorized wheelchairs as part of a larger initiative to curb provider billing fraud, the agency says

Coronavirus Demanding Focus Of US FDA’s Antiviral, Other Divisions

Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.

Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.

UsernamePublicRestriction

Register

MT021218

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel